Principal Financial Group Inc Ligand Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

  • $162 Billion
  • Q1 2024

A detailed history of Principal Financial Group Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 92,124 shares of LGND stock, worth $7.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,124
Previous 92,810 0.74%
Holding current value
$7.77 Million
Previous $6.63 Million 1.6%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024
SELL
$68.64 - $89.2 $47,087 - $61,191
-686 Reduced 0.74%
92,124 $6.73 Million
Q4 2023

Feb 07, 2024
SELL
$49.57 - $72.63 $62,854 - $92,094
-1,268 Reduced 1.35%
92,810 $6.63 Million
Q3 2023

Nov 02, 2023
SELL
$58.86 - $72.67 $234,380 - $289,371
-3,982 Reduced 4.06%
94,078 $5.64 Million
Q2 2023

Aug 07, 2023
SELL
$69.53 - $79.33 $251,003 - $286,381
-3,610 Reduced 3.55%
98,060 $7.07 Million
Q1 2023

May 09, 2023
SELL
$65.67 - $77.08 $124,707 - $146,374
-1,899 Reduced 1.83%
101,670 $7.48 Million
Q4 2022

Feb 09, 2023
BUY
$61.72 - $96.74 $76,841 - $120,441
1,245 Added 1.22%
103,569 $6.92 Million
Q3 2022

Nov 09, 2022
SELL
$0.01 - $107.56 $116 - $1.26 Million
-11,677 Reduced 10.24%
102,324 $8.81 Million
Q2 2022

Aug 10, 2022
SELL
$74.52 - $117.06 $627,085 - $985,059
-8,415 Reduced 6.87%
114,001 $10.2 Million
Q1 2022

May 09, 2022
SELL
$94.99 - $151.56 $811,499 - $1.29 Million
-8,543 Reduced 6.52%
122,416 $13.8 Million
Q4 2021

Feb 09, 2022
SELL
$127.69 - $165.85 $4.44 Million - $5.76 Million
-34,752 Reduced 20.97%
130,959 $20.2 Million
Q3 2021

Nov 09, 2021
BUY
$102.33 - $144.73 $5.72 Million - $8.09 Million
55,913 Added 50.92%
165,711 $23.1 Million
Q2 2021

Aug 10, 2021
BUY
$113.03 - $155.64 $993,420 - $1.37 Million
8,789 Added 8.7%
109,798 $14.4 Million
Q1 2021

May 10, 2021
BUY
$99.52 - $215.83 $1.24 Million - $2.69 Million
12,476 Added 14.09%
101,009 $15.4 Million
Q4 2020

Feb 08, 2021
SELL
$80.55 - $106.05 $848,594 - $1.12 Million
-10,535 Reduced 10.63%
88,533 $8.8 Million
Q3 2020

Nov 06, 2020
BUY
$89.56 - $126.72 $1.8 Million - $2.55 Million
20,104 Added 25.46%
99,068 $9.44 Million
Q2 2020

Aug 05, 2020
BUY
$68.28 - $123.65 $1.86 Million - $3.36 Million
27,209 Added 52.57%
78,964 $8.83 Million
Q1 2020

May 12, 2020
SELL
$63.37 - $107.88 $1.62 Million - $2.76 Million
-25,624 Reduced 33.11%
51,755 $3.76 Million
Q4 2019

Feb 05, 2020
SELL
$96.94 - $113.59 $330,177 - $386,887
-3,406 Reduced 4.22%
77,379 $8.07 Million
Q3 2019

Nov 13, 2019
SELL
$86.25 - $120.16 $348,881 - $486,047
-4,045 Reduced 4.77%
80,785 $8.04 Million
Q2 2019

Aug 12, 2019
SELL
$107.38 - $129.34 $689,164 - $830,104
-6,418 Reduced 7.03%
84,830 $9.68 Million
Q1 2019

May 10, 2019
SELL
$105.93 - $142.47 $317,472 - $426,982
-2,997 Reduced 3.18%
91,248 $11.5 Million
Q4 2018

Feb 14, 2019
SELL
$128.36 - $272.13 $12.1 Million - $25.7 Million
-94,407 Reduced 50.04%
94,245 $12.8 Million
Q3 2018

Nov 14, 2018
BUY
$211.18 - $274.49 $1.17 Million - $1.52 Million
5,528 Added 3.02%
188,652 $51.8 Million
Q2 2018

Aug 13, 2018
BUY
$150.77 - $207.98 $78,098 - $107,733
518 Added 0.28%
183,124 $0
Q1 2018

May 14, 2018
BUY
$138.63 - $182.62 $732,798 - $965,329
5,286 Added 2.98%
182,606 $30.2 Million
Q4 2017

Feb 13, 2018
BUY
$128.36 - $147.04 $2.02 Million - $2.31 Million
15,723 Added 9.73%
177,320 $24.3 Million
Q3 2017

Nov 02, 2017
BUY
$120.91 - $137.94 $19.5 Million - $22.3 Million
161,597
161,597 $22 Million

Others Institutions Holding LGND

# of Institutions
233
Shares Held
16.5M
Call Options Held
77.9K
Put Options Held
25K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.42B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email